MedTrace Logo

Quantitative Transmission Imaging Compared With MRI as Supplemental Screening for High Lifetime Risk of Breast Cancer

NCT07216274 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-12-05

No results posted yet for this study

Summary

This clinical trial compares the use of quantitative transmission imaging (QTI) to standard of care MRI as a supplemental screening tool for patients with a high lifetime risk of breast cancer. QTI is a single 3D ultrasound test intended to be used as an initial evaluation method for asymptomatic women identified with above-average risk for developing breast cancer. Using QTI may be an effective supplemental screening tool, compared to MRI for patients with a high lifetime risk of breast cancer.

Conditions

  • Breast Carcinoma

Interventions

DEVICE

QT Ultrasound Breast Scanner

Undergo Quantitative Transmission Imaging (QTI) using the QT Ultrasound Breast Scanner

OTHER

Questionnaire Administration

Ancillary studies

Sponsors & Collaborators

Principal Investigators

  • Tiffany M. Sae-Kho, MD · Mayo Clinic in Rochester

  • Christine U. Lee, MD, PhD · Mayo Clinic in Rochester

  • Chidi T. Nwachukwu, MD · Mayo Clinic

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-31
Primary Completion
2025-10-20
Completion
2025-10-20
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07216274 on ClinicalTrials.gov